ArticleMolecular therapy : the journal of the American Society of Gene Therapy2013
The epitope integration site for vaccine antigens determines virus control while maintaining efficacy in an engineered cancer vaccine.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- C-type lectin receptor DCIR contributes to hippocampal injury in acute neurotropic virus infection.Scientific reports · 2021Article
- CARD9 Deficiency Increases Hippocampal Injury Following Acute Neurotropic Picornavirus Infection but Does Not Affect Pathogen Elimination.International journal of molecular sciences · 2021Article
- Developing Picornaviruses for Cancer Therapy.Cancers · 2019Review
- Breaking tolerance with engineered class I antigen-presenting molecules.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- The early proximal αβ TCR signalosome specifies thymic selection outcome through a quantitative protein interaction network.Science immunology · 2019Article
- Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8Nature communications · 2018Article
- B7-H1 Influences the Accumulation of Virus-Specific Tissue Resident Memory T Cells in the Central Nervous System.Frontiers in immunology · 2017Article
- Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Molecular cancer therapeutics · 2016Article
- The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma.PloS one · 2016Article
- Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Article
- Article
- A CD8 T-cell epitope variant enhances immune targeting to a recombinant picornavirus vaccine antigen.Viral immunology · 2014Article
- An elite controller of picornavirus infection targets an epitope that is resistant to immune escape.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Picornaviruses have been developed as potential therapies for gene delivery and vaccination. One drawback to their use is the potential for recombination and viral persistence. Therefore, the engineering strategies used must take into account the possibility for virus escape. We have developed Theiler's murine encephalomyelitis virus (TMEV) as a potential vaccine vector for use in immunotherapy. This study shows that insertion of a vaccine epitope at a unique site within the TMEV leader protein can dramatically increase the type I interferon (IFN) response to infection and promote rapid viral clearance. This live virus vaccine maintains its ability to drive antigen-specific CD8(+) T-cell responses to a model antigen as well as to the weakly immunogenic tumor antigen Her2/neu. Furthermore, the epitope integration site does not affect the efficacy of this vaccine as cancer immunotherapy for treating models of melanoma and breast cancer as demonstrated by delayed tumor outgrowth and increased survival in animals implanted with these tumors. These findings show that an attenuated virus retaining limited ability to replicate nonetheless can effectively mobilize CD8(+) cellular immunity and will be important for the design of picornavirus vectors used as immunotherapy in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.